Incretin mimetics exenatide

Incretin mimetic Exenatide Mimic GLP-1C enhance prandial insulin secretion SC injectiond... 

Fig. 4. Peptide and chemical structure, respectively, of the incretin mimetics exenatide and liraglutide and the DPP inhibitors sitagliptin ((2R)A-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8//)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine) and vUdagliptin (l-[[(3-hydroxy-l-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine). (Modified from Drucker and Nanck 2006 [145]).

Table 2. Comparison of the incretin mimetics exenatide, exenatide LAR and liraglntide.

Byetta containing exenatide (incretin mimetic) is marketed by Lilly. 

Gryskiewicz K, Coleman CL Exenatide. A novel incretin mimetic hormone for the treatment of type 2 diabetes. Formulary 2005 40 86-90. 

Lilly/Amylin Byetta Exenatide incretin mimetics 430... 

Exenatide is an incretin mimetic that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. This increases insulin secretion when glucose levels are high. It is given subcutaneously as an adjunct in type 2 diabetes in patients already receiving metformin, a sulphonylurea, or both. 

Exenatide and liraglutide have been approved for use in both the USA and the EU. Several other incretin mimetics are... 

Exenatide is a dmg that is described as an incretin mimetic in that it has a strong stmctural resemblance to GLP-1. This dmg is a synthetic peptide based on a hormone, exendin-4, found in the saliva of the Gila monster. Research on this peptide showed that it had properties similar to GLP-1. Now, GLP-1 cannot be administered to patients with type 2 diabetes since it is rapidly inactivated in the body by DPP-4, as indicated above. Due to the stmctural similarity between GLP-1 and exendin-4, it was investigated as a GLP-1 mimetic and shown to work effectively. It was also shown to have a considerably longer half-life than GLP-1 as it was not broken down by DPP-4 as quickly as the natural analogue. 

---